EC Neurology

Introduction: Migraine is globally the second cause of disability. Recently, there have been developed new treatments against calcitonin gene-related peptide (CGRP).

Cases: We present two patients who have developed allergic reactions to anti-CGRP, causing its suspension. 

Discussion: Erenumab in the majority of cases is well tolerated, although there are some reports of severe hypersensitivity reactions. 

Nowadays, in clinical practice there is an anti-CGRP switch due to lack of response. 

Conclusion: We propose, anti-CGRP switch after hypersensibility reaction, with assessment by the Allergology service.

Keywords: Anti-Cgrp Switch; Hypersensitivity Reactions; DALYs (Disability Adjusted Life Years); Calcitonin Gene-Related Peptide (CGRP)

1. GBD 2016 Headache Collaborators. “Global, regional, and national burden of migraine and tension-type headache, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016”. The Lancet Neurology 11 (2018): 954-976.
2. Drellia K., et al. “Anti-CGRP monoclonal antibodies for migraine prevention: A systematic review and likelihood to help or harm analysis”. Cephalalgia7 (2021): 851-864.
3. Edvinsson L. “The Trigeminovascular Pathway: Role of CGRP and CGRP Receptors in Migraine”. Headache2 (2017): 47-55.
4. Ashina M., et al. “Migraine: epidemiology and systems of care”. Lancet10283 (2021): 1485-1495.
5. Isabwe GAC., et al. “Hypersensitivity reactions to therapeutic monoclonal antibodies: Phenotypes and endotypes”. The Journal of Allergy and Clinical Immunology 1 (2018): 159-170.e2.
6. Data sheet erenumab.
7. Sacco S., et al. “European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention - 2022 update”. The Journal of Headache and Pain1 (2022): 67.
8. Hong DI., et al. “Allergy to monoclonal antibodies: cutting-edge desensitization methods for cutting-edge therapies”. Expert Review of Clinical Immunology1 (2012): 43-52.